secwatch.observer — SEC 8-K summary
======================================

Issuer:     OmniAb, Inc. (OABI)
CIK:        0001846253
Form:       8-K
Filed at:   2022-11-15T23:59:59+00:00
Accession:  0001193125-22-285236
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OmniAb Q3 2022 revenue $6.9M, net loss $12.6M; completed spin-off from Ligand
-----------------------------------------------------------------------------

- Revenue $6.9M in Q3 2022 vs $6.3M in Q3 2021; net loss $12.6M vs $7.9M.
- Completed tax-free spin-off from Ligand and merger with Avista on Nov 1, 2022; net cash ~$96M.
- 68 active partners; 25 OmniAb-derived programs in clinic/commercial; 282 partner programs.
- Janssen received FDA and EU approval for TECVAYLI; OmniAb eligible for up to $35M in milestones.
- New platform deals with Dianthus, Hillstream, NGM Bio, TriPhase, Talem, and a stealth biotech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1846253/000119312522285236/0001193125-22-285236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1846253/000119312522285236/d372979d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-285236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer